Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PIK3CA H1047X refers to any missense mutation in the PIK3CA gene at amino acid position 1047 that results in increased PI3K enzymatic activity. This gain-of-function mutation is a common oncogenic driver, particularly in breast, colorectal, and bladder cancers, leading to enhanced cell proliferation, survival, and migration. The presence of H1047X mutations may impact treatment response and is being explored as a biomarker for targeted therapies.
PI3K inhibition
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PIK3CA H1047X.